UBS raises Amgen stock price target to $530 on diversification

Amgen reported third-quarter revenue of $10.4 billion, up 8% year over year and above the $10.1 billion consensus, while adjusted EPS of $6.45 rose 14% and beat the $5.79 estimate. The company raised fiscal 2026 revenue guidance by $500 million at the midpoint to $38.9 billion–$39.7 billion and adjusted EPS guidance by $0.40 at the midpoint to $22.90–$23.70; growth products including Imdelltra (+128%), Evenity (+39%) and Repatha (+37%) offset pressure on some older products. UBS lifted its price target to $530 from $470 and maintained Buy, amid broader analyst estimate increases; the article also notes a valuation concern at current levels.

Analysis

The key question is whether newer-product growth can keep replacing erosion in older franchises without requiring margin give-up. A broader set of meaningful products reduces dependence on any single launch, but annualized sales run-rates are not proof of durable demand: monitor persistence of uptake, payer access and net pricing, particularly as established products face competitive and biosimilar pressure. Flat 2027 margin guidance also tempers the case for extrapolating current EPS growth into accelerating operating leverage.

Near term, raised estimates and supportive analyst revisions can sustain momentum, but with shares already near a one-year high, much of the beat may be reflected in price. Over 1–3 months, execution and the next guidance update matter more than further target-price changes. Over 6–18 months, the structural test is whether newer franchises replace legacy revenue while preserving margins. The consensus risk is treating launch growth as a smooth portfolio-wide growth rate; product-level deceleration or price/mix pressure could expose that extrapolation. No valuation inputs here are sufficient to establish that the shares are cheap.

Key Decisions for Investors

• Do not chase the post-earnings strength solely on analyst target increases. For exposure, consider a modest long AMGN versus short XBI pair on a pullback, subject to checking relative valuation, borrow and beta; the intent is to isolate company execution from broad biotech risk.
• Treat the next 1–3 months as a confirmation window: track quarterly sales and guidance for Repatha, Evenity and Imdelltra alongside Prolia/Xgeva and Otezla erosion. Verify reported product-level trends and net pricing rather than relying on annualized run-rates.
• Falsify the long thesis if growth-product uptake materially decelerates, legacy erosion outpaces replacement, or management reduces the FY2026 outlook; also reassess if 2027 operating-margin guidance falls below the stated 45%–46% range.
• Keep position sizing disciplined: the stock's strong prior run and limited evidence here on valuation leave downside if execution merely meets elevated expectations. Revisit only after reviewing current price action, estimate revisions and the next earnings release.